SAFit2 is a potent and selective FKBP51 inhibitor (Ki = 6 nM) that modulates the AKT2-AS160 pathway and glucocorticoid signaling. It is a research tool for studying metabolic disorders, neuropsychiatric conditions, and chronic pain in preclinical models.